Fluticasone Propionate — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	Inhalation (metered-dose inhaler with spacer)	110-220 µg per dog (2 puffs of 110 µg) q12h	q12h	Duration: Long-term; taper to lowest effective dose Notes: Use with a canine aerosol chamber (e.g., AeroDawg). Rinse mouth after use to reduce oral candidiasis.
Cat	Inhalation (metered-dose inhaler with spacer)	110-220 µg per cat (2 puffs of 110 µg) q12h	q12h	Duration: Long-term; taper to lowest effective dose Notes: Use with a feline aerosol chamber (e.g., AeroKat). May be used as sole therapy or to reduce systemic corticosteroid dependence.
Horse	Inhalation (equine inhaler)	2000-4000 µg (2-4 puffs of 500 µg) q12h	q12h	Duration: Long-term; adjust based on clinical response Notes: Use with an equine aerosol delivery device. For heaves, combine with environmental management.
Dog	Topical (cream/ointment)	Apply thin film to affected area q12h	q12h	Duration: 5-7 days or as directed Notes: Avoid prolonged use on large areas or under occlusion. Not for ophthalmic use.
Cat	Topical (cream/ointment)	Apply thin film to affected area q12h	q12h	Duration: 5-7 days or as directed Notes: Avoid licking; use an Elizabethan collar if necessary.
Rabbit	Inhalation (nebulization)	0.5-1 mg (as solution for nebulization) q12h	q12h	Duration: 7-14 days or as directed Notes: Use a pediatric nebulizer mask. Monitor for stress during administration.

Clinical Indications & Species Uses

General Indications

Management of inflammatory and allergic conditions, particularly respiratory and dermatologic

Dog (Canine)

Inflammatory airway disease (chronic bronchitis)
Allergic dermatitis (topical)
Nasal inflammation (intranasal)
Eosinophilic bronchopneumopathy

Cat (Feline)

Feline bronchial asthma
Chronic bronchitis
Allergic dermatitis (topical)
Eosinophilic granuloma complex (topical)

Horse (Equine)

Recurrent airway obstruction (heaves)
Inflammatory airway disease
Allergic dermatitis (topical)

Rabbit & Small Mammals

Respiratory disease (e.g., pasteurellosis-associated inflammation) - adjunctive

Exotic & Other Species

Ferrets: Inflammatory airway disease; Small mammals: topical for dermatitis

Pharmacology & Mechanism of Action

Drug Class: Corticosteroid | Pharmacological Group: Glucocorticoid

Mechanism of Action: Fluticasone propionate is a synthetic fluorinated glucocorticoid with potent anti-inflammatory, anti-allergic, and immunosuppressive properties. It binds to the glucocorticoid receptor (GR) in the cytoplasm, leading to translocation into the nucleus where it modulates gene transcription. It upregulates anti-inflammatory genes (e.g., lipocortin-1, IL-10) and downregulates pro-inflammatory genes (e.g., cytokines, chemokines, adhesion molecules). It also inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis. Its high lipophilicity and receptor affinity result in prolonged tissue retention and once-daily dosing.

Pharmacodynamics: Fluticasone propionate exerts potent topical anti-inflammatory activity with minimal systemic effects due to high first-pass metabolism and low oral bioavailability. It reduces airway hyperresponsiveness, mucus secretion, and eosinophil infiltration in the lungs. It also decreases vascular permeability and inflammatory cell migration. In dermatological use, it suppresses pruritus and inflammation. Its relative anti-inflammatory potency is approximately 1,000 times that of hydrocortisone and 3 times that of budesonide.

⚡ Pharmacokinetics Summary

Absorption: After oral inhalation, a significant portion is swallowed but undergoes extensive first-pass metabolism in the liver, resulting in negligible systemic bioavailability (<1%). The fraction deposited in the lungs is absorbed systemically but is rapidly cleared. After topical application to skin, absorption is minimal but can increase with inflammation or occlusion.

Distribution: Fluticasone propionate is highly lipophilic, leading to extensive tissue distribution. It has a large volume of distribution (approximately 4.2 L/kg in humans). It crosses the placenta and is excreted in milk in small amounts.

Metabolism: Fluticasone propionate is rapidly metabolized in the liver via cytochrome P450 3A4 (CYP3A4) to inactive metabolites. It undergoes hydrolysis and oxidation to form 17β-carboxylic acid derivatives.

Excretion: Metabolites are primarily excreted in feces (approximately 90%) and urine (approximately 5%) as glucuronide and sulfate conjugates. The elimination half-life is approximately 7.8 hours in humans after IV administration.

Half-Life: Dog: ~1.5 hours (IV); Horse: ~2 hours (IV); Human: ~7.8 hours (IV)

Bioavailability: Oral: <1% due to extensive first-pass metabolism; Inhaled: approximately 20-30% of the inhaled dose reaches the lungs, with systemic bioavailability from the lung fraction being about 20%.

Protein Binding: Approximately 91% bound to plasma proteins (albumin and alpha-1-acid glycoprotein).

Available Formulations & Strengths

Metered-dose inhaler (MDI) 44 µg, 110 µg, 220 µg per actuation (Inhalation)

Nasal spray 50 µg per spray (Intranasal)

Topical cream 0.05% (Topical)

Topical ointment 0.005% (Topical)

Nebulizer solution (compounded) 0.5 mg/mL (compounded) (Inhalation (nebulization))

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to fluticasone propionate or any component
Systemic fungal infections (unless treated)
Viral infections (e.g., herpes keratitis) - topical use
Use in animals with pre-existing immunosuppression
Use in pregnant animals unless benefits outweigh risks (limited safety data)

Warnings & Clinical Precautions:

Inhaled fluticasone may cause adrenal suppression with prolonged use; taper slowly when discontinuing.
Monitor for signs of iatrogenic hyperadrenocorticism (polyuria, polydipsia, weight gain) with high doses or prolonged use.
In cats, use with caution in cases of diabetes mellitus; may cause insulin resistance.
In horses, avoid use in acute severe airway obstruction; use bronchodilators as needed.
Topical use on large wounds or broken skin may increase systemic absorption.
Do not use in eyes or ears with a perforated tympanic membrane.
Inhalation devices require proper technique; use spacers in small animals.
May delay wound healing; use with caution in animals with skin infections.
Not for use in food-producing animals due to lack of withdrawal data.

Adverse Effects & Reactions

Common:

Cough (transient after inhalation)
Oral candidiasis (with inhaled use)
Local skin irritation (topical)
Sneezing (intranasal)

Serious / Severe:

Adrenal suppression
Iatrogenic hyperadrenocorticism (Cushing's syndrome)
Growth suppression in young animals
Diabetes mellitus exacerbation
Gastrointestinal ulceration (with systemic absorption)
Immunosuppression leading to opportunistic infections

Rare:

Anaphylaxis
Bronchospasm (paradoxical)
Perforation of nasal septum (intranasal)
Osteoporosis (long-term systemic use)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin)	May increase fluticasone plasma levels and systemic effects; monitor for signs of corticosteroid excess.	High
Non-steroidal anti-inflammatory drugs (NSAIDs)	Increased risk of gastrointestinal ulceration and bleeding.	Moderate
Insulin or oral hypoglycemic agents	May reduce glycemic control; adjust antidiabetic therapy as needed.	Moderate
Diuretics (e.g., furosemide)	May enhance potassium depletion; monitor electrolytes.	Mild
Vaccines (live attenuated)	Immunosuppression may reduce vaccine efficacy or increase risk of infection.	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Adrenal suppression
Hyperglycemia
Polyuria and polydipsia
Weight gain
Behavioral changes (agitation, depression)
Gastrointestinal ulceration (with systemic absorption)

Emergency Treatment Protocol: Treatment is primarily supportive. Discontinue the drug and manage symptoms. In cases of acute overdose, consider gastric decontamination if ingestion is recent. Monitor for electrolyte imbalances and adrenal function. In severe cases, administer supportive care including fluids, electrolytes, and possibly insulin for hyperglycemia. Long-term overdose may require gradual tapering to avoid adrenal crisis.

Food Animal Withdrawal Times

Not approved for use in food-producing animals. Withdrawal times are not established; do not use in animals intended for food.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F), excursions permitted between 15-30°C (59-86°F).

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light and moisture. Keep canister away from open flame or high heat. Do not puncture or incinerate aerosol containers.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use (e.g., Flovent, Flonase).

Extra-Label (Off-Label) Use: In the US, fluticasone propionate is not FDA-approved for veterinary use; however, it may be prescribed under the Animal Medicinal Drug Use Clarification Act (AMDUCA) for extra-label use in animals. For food animals, extra-label use is prohibited if it results in violative residues.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Fluticasone propionate is a potent inhaled corticosteroid used primarily for the management of inflammatory airway diseases in small animals and horses. In cats, it is a cornerstone for treating feline bronchial asthma, often allowing reduction or discontinuation of systemic corticosteroids. In dogs, it is used for chronic bronchitis and inflammatory airway disease. In horses, it is effective for recurrent airway obstruction (heaves) when administered via inhalation. Topical formulations are used for localized dermatological conditions. Due to its high potency and low systemic bioavailability, it is preferred over systemic corticosteroids for long-term management. However, it is essential to use proper inhalation devices (spacers) to ensure drug delivery. Monitor animals for signs of adrenal suppression, especially with prolonged use. Taper doses gradually when discontinuing. Avoid use in animals with systemic infections unless appropriately treated. Always consider the risk-benefit ratio in pregnant or lactating animals.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)